Potently neutralizing and protective human antibodies against SARS-CoV-2
Vanderbilt University Medical Center · Washington University in St. Louis · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,191
total citations
- FWCI
- 26.07
- Percentile
- 100%
- References
- 69
Citations per year
Authors
41Topics & keywords
Topics
Keywords
- Monoclonal antibody
- Epitope
- Antibody
- Virology
- Neutralizing antibody
- Immunology
- Medicine
- Biology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAstraZeneca
- VUVanderbilt University
- VIVanderbilt Institute for Clinical and Translational ResearchAward: UL1TR002243
- MKMerck KGaA
- VUVanderbilt University Medical CenterAward: UL1TR002243
- NINational Institutes of HealthAwards: F31 AI145189, RR028106, NIH T32, F32 AI138392, T32 AI007151, -0001, COVID-19, 75N93019C00062, T32 AI095202, U01 AI150739, UL1TR002243, T32 AI138932, AI138392
- DADefense Advanced Research Projects AgencyAwards: HR0011-18-2-0001, 75N93019C00062
- ARAdvanced Research Projects Agency
- NCNational Center for Advancing Translational SciencesAward: UL1TR002243